HIV-positive non-small cell lung cancer
Conditions
Interventions
Experimental Group:Tislelizumab in combination with a standard-dose platinum-containing two-drug regimen (paclitaxel, albumin-bound paclitaxel, pemetrexed disodium, cisplatin, and carboplatin), follow
Control group:Tislelizumab in combination with a standard-dose platinum-containing two-drug regimen (paclitaxel, albumin-bound paclitaxel, pemetrexed disodium, cisplatin, and carboplatin), followed by
Sponsors
Guiyang Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients with NSCLC who are aged between 18 and 75 years, have been pathologically diagnosed and are at stage IIIC-IV of the eighth edition of AJCC. 2. Experimental group: Confirmed HIV, with viral load =1500/mm^3, platelet count >= 100,000 /mm^3, hemoglobin count >=6g/dL), normal liver function (bilirubin level =60ml/min); 6. There are measurable lesions in accordance with RECIST1.1 standards; 7. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined with a second primary tumor; 2. Complicated with severe internal diseases and unable to tolerate anti-tumor treatment; 3. Expected survival period <3 months; 4. Those who are lost to follow-up or have incomplete follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall response rate;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate; | — |
Countries
China
Contacts
Public ContactYong Hu
Guiyang Public Health Clinical Center
Outcome results
None listed